ImmuPharma AI Stock Analysis
ImmuPharma (25I) AI Stock Analysis
ImmuPharma
(Frankfurt:25I)
No summary available
ImmuPharma (25I) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 17.59M
- Dividend Yield
- ―
- Average Volume (3M)
- 16.25K
- Price to Earnings (P/E)
- -2.3
- Beta (1Y)
- 6.21
- Revenue Growth
- ―
- EPS Growth
- 8.57%
- Country
- Germany
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
ImmuPharma Business Overview & Revenue Model
Company Description
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead p...
ImmuPharma Peers Comparison
Overall Rating
GB:SBTX59Neutral
GB:SCLP49Neutral
GB:SAR47Neutral
GB:HEMO46Neutral
GB:POLB42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 59Neutral | GBP 12.31M | -26.39 | -5.25% | ― | 95.16% | 85.60% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | GBP 98.19M | -4.63 | 128.87% | ― | -100.00% | -30.39% | |
| 47Neutral | GBP 23.75M | -6.04 | -188.01% | ― | ― | 28.78% | |
| 46Neutral | GBP 46.90M | -3.76 | -409.57% | ― | ― | 18.57% | |
| 42Neutral | GBP 44.66M | -7.50 | -71.28% | ― | ― | 31.58% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:25I | ImmuPharma plc | 0.01 | -0.08 | -83.87% | |
| GB:SAR | Sareum Holdings | 14.50 | 0.75 | 5.45% | |
| GB:SCLP | Scancell Holdings | 81.00 | -17.00 | -17.35% | |
| GB:HEMO | Hemogenyx Pharmaceuticals Plc | 680.00 | -220.00 | -24.44% | |
| GB:SBTX | SkinBioTherapeutics plc | 4.75 | -11.00 | -69.84% | |
| GB:POLB | Poolbeg Pharma Ltd. | 5.85 | 1.80 | 44.44% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
